Mark Pearson

Mark Pearson leads the Cancer Pharmacology and Disease Positioning Department within the Oncology therapeutic area at Boehringer Ingelheim. The department focusses on profiling cancer cell directed therapeutics to identify development candidates. Previously, he held leadership positions in the target validation and identification department at Boehringer Ingelheim as well as at Pharma companies in England and Switzerland. Before joining industry, he received a degree in Biochemistry from the University of Oxford before completing his doctoral studies at the University of Manchester and subsequent post-doctoral studies at the European Institute of Oncology (IEO) in Milan with Professor Pelicci, where he studied the interaction between PML-RARalpha and p53.